A letter to the editor is presented in response to the article "Reported Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation" by B. M. Psaty and R. A. Kronmal in a previous issue.